You say of JP: "I don't think he could tell a fib if he tried...

You say of JP:
"I don't think he could tell a fib if he tried and his genuineness is so compelling"

You then go on to contradict that statement:
"the feeling I get is that they are under pressure doing all these trials (despite him saying they could do Phase 3 trials - I don't think it is realistic"

• JP was very clear on why they are cancelling the current PWS trial. He was also clear that they wanted to run it again with more favourable protocols.
• He was also crystal clear that Neuren could afford to run 2 Ph3 trials.
• And as for the pressure they are under, "doing all these trials", they're literally working tirelessly with the aim of doing a whole lot more trials.

I take JP at face value.

Like you, I think JP mentioning Reata was an eye opener, and I do think, if and when a TO comes, this will be the benchmark. But, in the Reata context, JP mentioned that Reata's value was for an FDA approved drug for 1 indication.

So my takeaway is that I agree with Nashezz that a TO this year is not a certainty.
FWIW, Goldenchook, on the Neuren Media and Analysts thread, posted what I think was the most thoughtful post on here in ages.